Drug Trial Radar · NCT07782476
Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
67
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Oct 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Helixon Biotechnology (Suzhou) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I/II, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN6005 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD). The study consists of three parts: Part A (single ascending dose in healthy participants), Part B (multiple ascending dose in AD patients), and Part C (multiple-dose efficacy and safety assessment in AD patients). The primary objectives are to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HXN6005.
Conditions
- Health Adult Subjects
- Atopic Dermatitis (AD)
Interventions
HXN6005Drug
Participants will be enrolled sequentially into one of two ascending dose cohorts and will receive a single subcutaneous dose of HXN6005.
PlaceboDrug
Participants will be enrolled sequentially into one of two ascending dose cohorts and will receive a single subcutaneous dose of placebo.
HXN6005Drug
Participants will be enrolled sequentially into one of two ascending dose cohorts and will receive multiple subcutaneous doses of HXN6005.
PlaceboDrug
Participants will be enrolled sequentially into one of two ascending dose cohorts and will receive multiple subcutaneous doses of placebo.
HXN6005Drug
Participants will be enrolled in parallel into one of two dose cohorts and will receive multiple subcutaneous doses of HXN6005.
PlaceboDrug
Participants will be enrolled in a single cohort and will receive multiple subcutaneous doses of placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A Adverse eventsTime frame: Up to day 141
- Part B Adverse EventsTime frame: Up to day 197
- Part C EfficacyTime frame: Up to day 113
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.